Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (4635)	11/17/1999 8:19:00 AM
From: David M. Gloss	Read Replies (2) \| Respond to of 4891

New Data Indicate That the Antiviral 'Substance R' May Enhance AIDS Cocktail Therapy; Dr. Hirschman of Advanced Viral Research Corp. Presents Findings at Conference MCLEAN, Va.--(BW HealthWire)--Nov. 17, 1999--Shalom Z. Hirschman, M.D., President and CEO of Advanced Viral Research Corp. (OTCBB:ADVR), reported yesterday that the experimental drug, Substance R (Reticulose(TM)), appears to "turn on" the body's beneficial response to fight viral infections, including HIV (human immunodeficiency virus) and HPV (human papilloma virus). Advanced Viral Research Corp. is developing Substance R, a non-toxic peptide-nucleic acid, as a broad spectrum antiviral drug. Speaking at a Cambridge HealthTech Institute conference on chemokines and chemokine receptors -- proteins that play an important role in trafficking immune system function -- Dr. Hirschman, an internationally-recognized authority in infectious diseases, presented case studies of two AIDS patients treated with Substance R. Both patients were initially unable to tolerate the AIDS cocktail called HAART (highly active antiretroviral therapy). When treated with a combination of Substance R and HAART, however, both experienced a dramatic drop in viral load, increases in weight and CD4 positive cell count, and an improved quality of life. "Clinical results of the therapeutic efficacy of Substance R combined with HAART are very encouraging," said Dr. Hirschman. He cautioned against regarding Substance R as a "magic bullet," but expressed optimism about research findings to date. Substance R Case Studies Two patients were treated with Substance R combined with a HAART drug cocktail of azidothymidine (AZT), lamivudine, a protease inhibitor and nevirapine. Prior to combination therapy, both patients did not tolerate the cocktail treatment alone. Moreover, while solely on HAART, both experienced increases in viral load. At the beginning of combination therapy, "Patient P" had a high viral load, a low CD4 positive cell count and weighed only 70 pounds. After three months on Substance R plus HAART, however, his viral load was undetectable. This patient felt so well that he discontinued treatment on his own, and his viral load increased. When he resumed treatment, his viral load again became undetectable and has remained so for over a year. "Patient P's" CD4 positive count is now about 130 cells per microliter. "Patient N" began treatment with a high viral load and a CD4 positive cell count of only 50 per microliter. He weighed less than 100 pounds. After combination therapy, he weighs more than 200 pounds, his viral load is undetectable, and his CD4 positive cell count is greater than 400 per microliter. Substance R + Cytokine, Chemokine Stimulation Dr. Hirschman also presented data from experiments conducted at the company's Advanced Viral Research Institute, indicating that Substance R stimulates several chemokines, including interferon gamma and interleukin-8. Research also showed that Substance R interferes with viral replication and that it decreases production of CCR5 and CXCR4, the two co-receptors required for HIV attachment to cells. About Advanced Viral Research Corp. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new, effective therapies for viral and other diseases, which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Substance R (Reticulose(TM)), is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Substance R (Reticulose(TM)) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. CONTACT: Bratskeir & Company, New York Jill Miller Mike Rosen 212/679-2233

To: Kingfisher who wrote (4635)	11/17/1999 11:15:00 PM
From: Kingfisher	Read Replies (2) \| Respond to of 4891

In the ADVR news release today it was stated that "Prior to combination therapy, both (AIDS) patients did not tolerate the cocktail treatment alone. Moreover, while solely on HAART, both experienced increases in viral load." As you know, it is further indicated in the news release, after combining Substance R with their cocktails the data support the fact that their was a substantial improvement in the health of both these AIDS patients. It appears to me that these AIDS patients would, most probably, be dead if they did not combine Substance R with the particular cocktail they were taking. What is also evident to me is that these two AIDS patients were very fortunate to have had Substance R available. Other individuals who may find themselves in such an unfortunate strait may now have NO OTHER RECOURSE BUT TO COMBINE SUBSTANCE R with their AIDS cocktail, unless there is some other drug available that can do as good a job as Substance R has done for this Parisian and New Yorker. Fortunately, under the compassionate-use rules individuals who find themselves in such a situation can obtain Substance R, if they know about it. Also, I feel that Martin Delaney of the San Francisco-based AIDS patient advocacy group Project Inform, and David Gilden editor of Treatment Issues, a news letter published by the Gay Mens Health Crisis of New York, if they are truly advocates for AIDS patients, should begin pushing for immediate trials to get Substance R FDA approved. To refresh you memories, in the Barron's May 20,1996 Erick Savitz article Martin Delaney was quoted as saying "This thing (Reticulose) has been around since the 1930s, and it's been sold for everything". and Dave Gilden was quoted as saying "I've seen the Hirschman abstract (Biomedicine '96 Poster Session) and it seemed not to be very definitive. I'd be surprised if it (Reticulose) really did something". I don't feel that the faithful posters and lurkers of this thread, and all other ADVR Boards, are at all surprised [as Dave and Martin should be today] at the success that Dr. Hirschman has had in proving what he said about the merits of Reticulose in that Barron's article are true.